|
|
||||||||
Center for Immunology and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The model system we used to explore the peptide specificity of thymic selection uses the OT-I TCR-transgenic mouse. The OT-I TCR recognizes the chicken OVA 257264 peptide, SIINFEKL (OVAp), in the context of Kb. Initial experiments using FTOC showed that the peptide EIINFEKL (E1), an antagonist variant of the OVAp peptide, promoted positive selection of OT-I cells, whereas OVAp itself caused deletion (10, 11). The half-life of OT-I binding to E1-Kb was subsequently found to be 44 times shorter than that to OVAp-Kb when measured at 37°C (12). If organ cultures appropriately mimic in vivo development, these data strongly suggest that kinetic discrimination is the basis for the differential response of thymocytes during positive and negative selection. However, the development of CD8 T cells in FTOC has been noted under conditions that would not be permissive for CD8 development in vivo (13), and it has been suggested that CD8 T cells might develop directly from DN precursors in organ cultures, bypassing the double-positive (DP) stage of development (14, 15). Furthermore, in two cases where peptides that were identified as positive selection ligands using FTOC were expressed in vivo as transgenes, positive selection was not observed (16) (and M. Bevan, unpublished observations).
For these reasons, it was important to determine whether the E1 low affinity ligand could promote positive selection of OT-I thymocytes in vivo when presented endogenously by cortical epithelial cells. In this study we created a transgenic mouse expressing the E1 peptide using the human keratin 14 (K14) promoter, which has been shown to allow expression in cortical epithelial cells (17). We found that the presence of E1 in vivo efficiently restored positive selection of OT-I T cells, but did not increase the size of the CD8 repertoire in non-TCR-transgenic mice. The implications of these observations are discussed.
| Materials and Methods |
|---|
|
|
|---|
The adenovirus E19/3K signal sequence-peptide expressing construct was generated using a multistep PCR procedure to produce insert oligomers coding for the adenovirus signal sequence (MRYMILGLLALAAVCSAA) and the E1 peptide (EIINFEKL) or the SIY peptide (SIYRYYGL). The PCRs were performed with three oligomers: O1 (5'-GGG AAG CTT ACG ATG AAA TAC ATG ATC CTG GGC CTG CTG-3') with a HindIII site at the 5' terminus; O2 (5'-GGC CTG CTG GCC CTG GCC GCC GTG TGC AGC GCT GCC-3'), and an O3 for E1 (5'-TTT CTC GAG TCA CAG CTT CTC GAA GTT GAT GAT CTC GGC AGC GCT-3') or O3 for SIY (5'-TTT CTC GAG TCA CAG GCC GTA GTA CCT GTA GAT GCT GGC AGC GCT-3'), with an XhoI site at the 5' terminus. The terminal base pairs of O2 were complementary to O3 and permitted their joining thorough PCR. Similarly, the terminal base pairs of O1 were complementary to O2, permitting construction of the desired insert, including sequences from O1 to O2. The O2 and O3 oligomers were initially joined using a 50-µl PCR consisting of PCR buffer (10x assay buffer B; Fisher, Pittsburgh, PA), 2.5 mM MgCl2, 300 µM dNTPs, and oligomers at 20 µg/ml. The cycle conditions were 95°C for 30 s, 30°C for 60 s, and 72°C for 30 s for a total of 30 cycles. This was followed by a second PCR in which the O1 and O3 oligomers were added to 5 µl of the first PCR. The second reaction consisted of 10 cycles as described above, followed by 30 cycles of 95°C for 1 min and 72°C for 2 min. The resultant products were then digested with HindIII and XhoI and directly cloned into the pcDNA3.1 vector (Invitrogen, Carlsbad, CA), and the orientation and fidelity of the cloning were confirmed by sequence analysis.
The K14 promoter construct was a gift from E. Fuchs (University of Chicago, Chicago, IL). A number of modifications to the K14 vector were performed before inserting the SS peptide, including conversion of the HindIII (position 4770) site to a KpnI and creation of HindIII and XhoI sites at the BamHI site (position 2150). Sequence analysis confirmed the fidelity of the cloning. The excised construct was sent to The Jackson Laboratory (Bar Harbor, ME) or University of Minnesota Cancer Center for microinjection into C57BL/6 embryos. Three founders were obtained for K14-SS-E1, and two were obtained for K14-SS-SIY.
The following primers were used in a PCR to determine whether the mice were transgenic for K14-SS-peptide: forward, 5'-CCC TTT ACA TAC ATT GTC CGC ATT-3'; and reverse, 5'-TTCGAACCTAGGAGCCATT-3'. These mice were bred to the OT-I TCR or 2C TCR-transgenic mice on an H-2b wild-type or TAP-deficient background.
Flow cytometry
Four-color staining was performed using FITC-labeled
anti-B20.1 (the transgenic V
2 chain), PE-labeled anti-CD4
(BD PharMingen, San Diego, CA), and biotin-labeled anti-CD5, CD69,
heat-stable Ag, or CD8
(BD PharMingen), followed by TriColor
or CyChrome-labeled streptavidin (BD PharMingen), and
allophycocyanin-labeled anti-CD8
(BD PharMingen). The
cells were analyzed on a FACSCalibur (BD Biosciences, Mountain View,
CA) using CellQuest software.
CD69 up-regulation assay
Splenocytes from a C57BL/6 TAP-deficient mouse were cultured with or without peptide for 1 h at room temperature. Unbound peptide was washed away, and the cells were plated at a concentration of 5 x 105/well in a round-bottom 96-well plate. Lymph node cells or splenocytes were excised from the different OT-I strains and placed at 5 x 105/well. The cells were spun together at 1000 rpm for 5 min and then placed at 37°C for 3, 8, or 24 h. The cells were stained with FITC-anti-CD69, PE-anti-CD4, and allophycocyanin-anti-CD8 (BD PharMingen). At least 1000 CD8 events were collected and analyzed using a FACSCalibur with CellQuest software (BD Biosciences).
Proliferation assay
Lymph node cells from OT-I or OT-I-TAPo-E1
mice were suspended at a concentration of 15 x
107 cells/ml in HBSS. After warming the cells to
37°C, they were stained with CFSE (Molecular Probes, Eugene, OR) for
10 min at 37°C with occasional mixing. After 10 min ice-cold RPMI
1640 medium containing 10% serum was added, and the cells were
recovered by centrifugation. The cells were incubated with
TAPo splenocytes pulsed in the presence or the
absence of 100 nM OVAp for 44 h at 37°C. At this time the cells
were stained with biotin anti-CD69, followed by
allophycocyanin-labeled anti-CD8-
and streptavidin-PerCP. At
least 10,000 CD8 events were collected and analyzed using a FACSCalibur
with CellQuest software (BD Biosciences).
CTL assay
Lymph node cells from wild-type OT-I or OT-I-TAPo-E1 mice were stimulated in the presence of OVAp in vitro for 5 days. The cells were harvested and used as effectors in a chromium release assay with EL4 target cells as previously described (10).
| Results and Discussion |
|---|
|
|
|---|
To test whether the low affinity ligand, E1, could promote positive selection in OT-I mice in vivo, we created peptide-transgenic mice. We chose a strategy that would direct loading of the peptide into MHC molecules and presentation at the cell surface in a TAP-independent manner. This allowed us to ask whether positive selection, which is impaired in TAP-deficient animals, could be restored by peptide in vivo. The transgene construct encoded a fusion protein consisting of an endoplasmic reticulum (ER) signal sequence followed by the eight amino acids of the peptide. Fusion proteins of a similar nature have been shown to target peptides to the ER in a TAP-1-independent manner in vitro (18) and in vivo (16, 19). Once in the ER, the peptide is cleaved, presumably by signal peptidase, and is presented in the context of MHC class I molecules at the cell surface (18). We also created transgenic mice expressing the Kb binding peptide SIYRYYGL (SIY) as a control (20). Transient transfection of the fusion protein constructs into tumor cells confirmed that the peptides were presented by Kb to T cells in a TAP-independent manner (data not shown).
The fusion protein was expressed under control of the human K14 promoter (17, 21). K14 is expressed in epithelial cells in the thymus and in basal cells of the skin and esophagus. Specifically, we were interested in obtaining expression in epithelial cells of the thymic cortex, the microenvironment in which positive selection occurs (22). The human K14 promoter was shown to reproducibly direct expression of transgenes in thymic cortical epithelial cells (17, 23, 24) (I. Williams and I. Frazier, unpublished observations).
An E1 transgene restores positive selection of OT-I cells in vivo
It was previously observed that E1 peptide induced positive
selection of CD8+ T cells in OT-I
2-microglobulino mice (10, 11) and OT-I TAPo mice (15)
in FTOC. To test whether this peptide could induce positive selection
of OT-I cells in vivo, we crossed the K14-E1 strain to OT-I and
backcrossed to the TAPo background. The thymus,
spleen, and lymph node cells were compared with those of
OT-I-TAPwt (a control for positive selection) and
OT-I-TAPo (a control for no selection). Fig. 1
shows cell surface levels of CD4, CD8,
and the OT-I-transgenic
-chain (V
2). The E1 transgene efficiently
restored positive selection of CD8 single-positive (CD8SP) thymocytes
in OT-I-TAPo mice. There was a dramatic increase
in both the level of TCR on total thymocytes and the percentage and
number of TCRhigh CD8SP (Fig. 1
A).
Additionally, E1-transgenic mice showed a distinct population of
CD4+CD8low cells that were
absent in OT-I-TAPo mice. This population was
also quite prominent in the OT-I wild-type (OT-I) thymus and was
previously shown to be a transitional population between DP precursors
and CD8 single-positive mature cells (25). The apparent
increase in CD4+CD8- cells
(5 to 11%) between OT-I-TAPo and
OT-I-TAPo-E1 mice does not reflect an increase in
positive selection to the CD4 lineage. In fact, the absolute number of
mature (heat-stable Ag low) CD4+
thymocytes was 2- to 6-fold lower in OT-I-TAPo-E1
mice compared with OT-I-TAPo mice. This decrease
in CD4 selection is reflected in the spleen as well (Fig. 1
B).
|
The positive effect of the K14-E1 transgene on selection of CD8 T cells
in OT-I-TAPo mice was also reflected in spleen
and lymph node populations (Fig. 1
B). The percentage and
number of V
2high CD8+ T
cells are increased in OT-I-TAPo-E1 compared with
those in OT-I-TAPo mice. Surprisingly, the extent
of restoration appeared somewhat smaller in the periphery than in the
thymus (Fig. 1
, compare A with B). Typically, the
reverse situation is seen, where positive selection in the thymus is
impaired, but large numbers of peripheral cells can accumulate
(27). The observation that the K14-E1 transgene
efficiently promoted positive selection in the thymus but did not
result in a large peripheral population may reflect an unavailability
of the E1 peptide in the periphery to sustain naive T cell survival.
Recent data suggest that mature T cell survival may require recognition
of self MHC molecules on dendritic cells (28). The
potential cross-presentation of skin Ags by dendritic cells in lymphoid
organs may not be efficient enough in the absence of
TAPo to support naive T cell survival in the
OT-I-TAPo-E1 mouse strain. This possibility is
currently under investigation.
Positive selection of CD8+ T cells is peptide specific
The fact that selection of OT-I thymocytes was restored suggests
that the E1 peptide was present at an appropriate level and in the
proper thymic compartment to influence positive selection. However, it
was possible that any Kb binding peptide
expressed by this promoter could restore positive selection by
stabilizing Kb molecules at the surface of
cortical epithelial cells. Thus, we examined mice expressing the
peptide SIYRYYGL (SIY) under the control of the K14 promoter. This
peptide is a target Ag for the 2C TCR-transgenic. Thus, we analyzed
2CxK14-SIY mice to confirm the in vivo expression of the SIY peptide.
In 2CxK14-SIY mice, the 2C TCR clonotype-positive DP cells were reduced
in number by 50-fold in the presence of K14-SIY (data not shown),
confirming thymic expression of the Ag in the cortex. To determine
whether positive selection is peptide specific, we crossed K14-SIY mice
with OT-I-TAPo TCR-transgenic mice. We found that
positive selection of OT-I T cells was not restored in these animals
(Fig. 2
A) as it was by K14-E1.
To further test whether peptide specificity is important in positive
selection, we crossed the 2C TCR-transgenic mice to the K14-E1 strain.
As shown in Fig. 2
B, positive selection in
2C-TAPo mice was not restored by K14-E1 as it was
in OT-I-TAPo mice. Finally, to test whether the
addition of a single peptide in TAPo mice would
restore selection of CD8 T cells, we looked at the CD8 compartment in
TAPo-E1 mice. We found that the K14-E1 transgene
had no detectable effect on the percentage or number of polyclonal CD8
T cells in non-TCR-transgenic TAPo mice (Fig. 2
C). Together, these data confirm the FTOC data, suggesting
that positive selection is a peptide-specific process and that
individual peptides do not support the selection of a large fraction of
the repertoire when expressed at low levels. Although the E1 peptide
may have caused subtle alterations in the repertoire in
non-TCR-transgenic mice, it did not have a large effect on the size of
the CD8 compartment. This is in contrast to the increase in CD8
(29) or CD4 T cells (2, 3, 5) observed in
other models in which the MHC-self peptide diversity is restricted to a
single complex. Unlike those other experimental systems, we did not
observe an up-regulation of cell surface MHC levels in
E1-TAPo cells in vitro, and this mouse probably
did not have high levels in vivo (data not shown).
|
We wanted to determine whether the cells that matured in
OT-I-K14-E1-TAPo mice were functional. We tested
lymph node cells for their ability to respond to the antigenic peptide
or to low affinity variants of it. Interestingly, there was a delay by
CD8 T cells from OT-I-TAPo-E1 mice in the
up-regulation of CD69 in response to all ligands tested (Fig. 3
, A and B). At
3 h CD8 T cells from OT-I-TAPo-E1 mice had a
50% lower surface expression of CD69 compared with normal OT-I CD8 T
cells. However, by 24 h both populations expressed equivalent
levels of CD69 in response to all ligands (Fig. 3
A).
Interestingly, this delay was not reflected by a shift in the
dose-response curve to OVAp even at low doses or at early time points
(Fig. 3
B) or to a shift in the dose response to ligands of
lower affinity (data not shown). Moreover, there was no difference
between the two populations in proliferation, as assessed by a CFSE dye
dilution assay at 48 h (Fig. 3
C). The similarity
between the populations was observed at 36, 48, and 60 h and at
various peptide doses (not shown). We also generated CTL lines from
OT-I and OT-I-TAPo-E1 spleen cells and observed
that their cytolytic activity against peptide-coated targets was
equivalent (Fig. 4
), although we
acknowledge that the in vitro culture may have selected for the most
highly reactive responders. Taken together, these data suggest that
although there is a slight lag in the response of CD8 T cells from
OT-I-TAPo-E1 mice, it is not reflected in
decreased sensitivity and does not hinder them from making a functional
response to Ag, at least in vitro.
|
|
- and
-chains were expressed at
similar levels between the two populations (Fig. 4
expression, there was a decrease in CD8
expression in cells from OT-I-TAPo-E1 mice (Fig. 4
The lag in response might be due to the slight differences in CD5 and
CD8
expression levels on cells from
OT-I-TAPo-E1 mice. Lower coreceptor and increased
CD5 levels have been noted in TCR transgenics expressing agonist or
stimulatory ligands in vitro and in vivo (11, 30, 31, 32).
Here we note the effect of a low affinity variant that promoted
positive selection in the thymus. These data suggest that the presence
of E1 in vivo forces a molecular compensation in developing thymocytes
that adjusts their response through the TCR. Alternatively, the effect
might be achieved not by receptor-ligand-driven changes in the cell,
but by selection of only those cells that had a predetermined cell
surface level of these molecules. However, if this were the case, we
would expect to see a large decrease in cell number in the thymus of
OT-I-TAPo-E1 mice, which we did not. The CD8
and CD5 data argue more for a conversion than a selection, because
virtually all preselection DP thymocytes express a high level of CD8
and a low level of CD5. However, upon selection
OT-I-TAPo-E1 thymocytes have uniformly lower
levels of CD8
and higher levels of CD5 than
OT-Iwt thymocytes. In addition, in vitro systems
have shown that CD8 levels may be directly down-regulated to modify the
response (33). Recently, Love and coworkers examined the
level of CD5 in a number of different TCR-transgenic systems
(32). Their studies showed that positive selection
up-regulates CD5 levels and that CD5 is even further up-regulated under
negative selection conditions. CD5 was shown to be a negative regulator
of cell signaling (34, 35). Taken together these
data provide a model in which modulation of the TCR signal by CD5 to
enhance selection can be envisioned. Our data support this model.
However, it has been suggested that CD5 and CD8
do so by altering
the activation threshold (13, 30). In an experimental
system using an lymphocytic choriomeningitis virus-specific TCR,
it was shown that the spectrum of activating ligands for a given mature
TCR is altered depending on the ligands that are present in the thymus
during selection (36). Another experimental system has
supported the model of T cell tuning in development. The 2C TCR is
normally positively selected on Kb, but is
alloreactive to Ld. When 2C TCR-transgenic T
cells were positively selected by low levels of
H-2Ld, they were unable to respond to endogenous
levels of the self peptide p2Ca-Ld complexes
(37). However, addition of exogenous p2Ca could induce a T
cell response. This suggests that the 2C thymocytes were modified so
that a response to the selecting ligand at low concentrations was not
detected, but at higher concentrations the selecting ligand activated
mature T cells. In our system the slight differences in CD5 and CD8
receptor levels correlate with a delayed response, rather than an
altered threshold.
Our study has shown that the presence of E1 in vivo is unable to restore positive selection of a diverse TCR repertoire in TAPo mice, but is able to restore positive selection of functional OT-I CD8+ T cells. These data support a model in which immature thymocytes are positively selected and modified by interactions with discrete self peptides.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Kristin Hogquist, Department of Laboratory Medicine and Pathology, University of Minnesota, Box 334 Mayo, 420 Delaware Street Southeast, Minneapolis, MN 55455. E-mail address: hogqu001{at}tc.umn.edu ![]()
3 Abbreviations used in this paper: FTOC, fetal thymus organ culture; K14, keratin 14; DP, double positive; ER, endoplasmic reticulum. ![]()
Received for publication June 22, 2000. Accepted for publication March 30, 2001.
| References |
|---|
|
|
|---|
-chain in response to an altered peptide ligand enables developing thymocytes to escape negative selection. Cell Immunol. 175:111.[Medline]

T cell receptor can replace the 
receptor in the development of 
lineage cells. Immunity 5:343.[Medline]
during epidermal development and differentiation. Genes Dev. 5:714.
2-microglobulin transgene. J. Exp. Med. 181:787.This article has been cited by other articles:
![]() |
D. Gil, A. G. Schrum, M. A. Daniels, and E. Palmer A Role for CD8 in the Developmental Tuning of Antigen Recognition and CD3 Conformational Change J. Immunol., March 15, 2008; 180(6): 3900 - 3909. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ribot, G. Enault, S. Pilipenko, A. Huchenq, M. Calise, D. Hudrisier, P. Romagnoli, and J. P. M. van Meerwijk Shaping of the Autoreactive Regulatory T Cell Repertoire by Thymic Cortical Positive Selection J. Immunol., November 15, 2007; 179(10): 6741 - 6748. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mayerova, L. Wang, L. S. Bursch, and K. A. Hogquist Conditioning of langerhans cells induced by a primary CD8 T cell response to self-antigen in vivo. J. Immunol., April 15, 2006; 176(8): 4658 - 4665. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Yu, J. Mao, Y. Wu, H. Luo, and J. Wu Ephrin-B1 Is Critical in T-cell Development J. Biol. Chem., April 14, 2006; 281(15): 10222 - 10229. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Rubin and T. M. Hermanson Plasticity in the positive selection of T cells: affinity of the selecting antigen and IL-7 affect T cell responsiveness Int. Immunol., July 1, 2005; 17(7): 959 - 971. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gil, A. G. Schrum, B. Alarcon, and E. Palmer T cell receptor engagement by peptide-MHC ligands induces a conformational change in the CD3 complex of thymocytes J. Exp. Med., February 22, 2005; 201(4): 517 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Matsumoto, G. R. Leggatt, J. Zhong, X. Liu, R. L. de Kluyver, T. Peters, G. J. P. Fernando, A. Liem, P. F. Lambert, and I. H. Frazer Impaired Antigen Presentation and Effectiveness of Combined Active/Passive Immunotherapy for Epithelial Tumors J Natl Cancer Inst, November 3, 2004; 96(21): 1611 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fridkis-Hareli, P. A. Reche, and E. L. Reinherz Peptide Variants of Viral CTL Epitopes Mediate Positive Selection and Emigration of Ag-Specific Thymocytes In Vivo J. Immunol., July 15, 2004; 173(2): 1140 - 1150. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mayerova and K. A. Hogquist Central Tolerance to Self-Antigen Expressed by Cortical Epithelial Cells J. Immunol., January 15, 2004; 172(2): 851 - 856. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. McGargill, D. Mayerova, H. E. Stefanski, B. Koehn, E. A. Parke, S. C. Jameson, A. Panoskaltsis-Mortari, and K. A. Hogquist A Spontaneous CD8 T Cell-Dependent Autoimmune Disease to an Antigen Expressed Under the Human Keratin 14 Promoter J. Immunol., August 15, 2002; 169(4): 2141 - 2147. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |